T-705 (Favipiravir)

Catalog No.: A11590

viral RNA polymerase inhibitor

T-705 (Favipiravir)

T-705 (Favipiravir) Chemical Structure

CAS NO. 259793-96-9

T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.

Availability: In stock

Package Price Qty
10 mg
$65.00
25 mg
$80.00
50 mg
$90.00
100 mg
$135.00
Custom Size Get quote

Free Overnight Delivery on orders over $500

Next day delivery by 10:00 a.m. Order now.

Warning Products are for laboratory research use only. Not for human use. We do not sell to patients.
  • Liva Checkmahomed, .et al. In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses, Viruses, 2020, Oct; 12(10): 1139 PMID: 33049959
  • JE Comer, .et al. Filovirus Virulence in Interferon α,β and γ Double Knockout Mice, and Treatment with Favipiravir, Viruses, 2019, Feb 3;11(2). pii: E137 PMID: 30717492
  • Haejin Chun, .et al. Efficient antiviral co-delivery using polymersomes by controlling the surface density of cell-targeting groups for influenza A virus treatment, Polym Chem, 2018, 9: 2116-2123
  • Baz M, .et al. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus, Viruses, 2018, Nov 3;10(11) PMID: 30400276
  • Ji-Ae Kim, .et al. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models, Viruses, 2018, Feb; 10(2): 72 PMID: 29425176
  • Ma J, .et al. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo, Antiviral Res, 2018, Feb;150:112-122 PMID: 29253498
  • Sehee Park, .et al. Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice, PLoS One., 2014, 9(7): e101325 PMID: 24992479

Biological Activity

T-705, a substituted pyrazine compound, has been found to exhibit potent anti-influenza virus activity in vitro and in vivo.

Targets
RNA-dependent RNA polymerase
In vitro DMSO 29 mg/mL (184.59 mM)
Water Warmed: 5 mg/mL (31.82 mM)
Ethanol Warmed: 21 mg/mL (133.67 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 63.65 mL 318.27 mL 636.54 mL
0.5 mM 12.73 mL 63.65 mL 127.31 mL
1 mM 6.37 mL 31.83 mL 63.65 mL
5 mM 1.27 mL 6.37 mL 12.73 mL

*The above data is based on the productmolecular weight 157.1. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Catalog Num A11590
Actions Inhibitor
CAS No. 259793-96-9
Formula C5H4FN3O2
M. Wt 157.1
Purity >98%
Synonyms T705, T 705
SMILES C1=C(N=C(C(=O)N1)C(=O)N)F
Storage

Store lyophilized at -20ºC, keep desiccated.
In lyophilized form, the chemical is stable for 36 months.
In solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Tags

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

Product Questions

Product Questions

No Questions
Keywords:buy T-705 (Favipiravir) | T-705 (Favipiravir) Supplier | purchase | cost | manufacturer | order | distributor | buy 259793-96-9| 259793-96-9 Supplier | purchase 259793-96-9 | 259793-96-9 cost | 259793-96-9 manufacturer | order 259793-96-9 | 259793-96-9 distributor
Rewards